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Abstract: In 2003 a consensus group on new-generation antihistamines (CONGA) defined 
the characteristics required for a third-generation H1 antihistamine as there had been much 
controversy about this issue since the early 1990s. One of the antihistamines that had been 
claimed to belong to such a group is the second-generation antihistamine, ebastine. The 
objective of this review is to analyze the pharmacology of ebastine, in light of the CONGA 
recommendations for the development of new-generation antihistamines: (1) anti-inflammatory 
properties, (2) potency, efficacy and effectiveness, (3) lack of cardiotoxicity, (4) lack of drug 
interactions, (5) lack of CNS effects, and (6) pharmacological approach. Ebastine seems to 
have anti-inflammatory properties that help to ameliorate nasal congestion, though this has not 
yet been conclusively demonstrated. Its pharmacological–therapeutic profile does not differ 
greatly from that of other second-generation antihistamines. Its cardiac safety has been widely 
assessed and no cardiac toxicity has been found at therapeutic doses despite initial concerns. 
The risk of potentially relevant drug interactions has been investigated and ruled out. Ebastine 
does not produce sedation at therapeutic doses and drug interaction studies with classical CNS 
depressants have not demonstrated a synergistic effect. Pharmacologically, ebastine is an H1 
inverse agonist. Perhaps the answer to the quest for new-generation antihistamines lies not only 
in H1 but in a combined approach with other histamine receptors.
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Introduction
Allergic diseases are among the commonest causes of chronic ill health.1 Discovered in 
the early 20th century, histamine is one of the major mediators of allergic reactions.2,3 
The work of the Swiss-Italian pharmacologist Daniel Bovet led to the discovery 
and production of H1 receptor antihistamines for allergy relief and earned him the 
Nobel Prize for physiology or medicine in 1957.4 The first antihistamine, 929 F 
(thymo-ethyl-diethylamine), was identified by Bovet and Staub in 1937,5,6 and since 
then there have been great advances in the development of more efficacious and safer 
antihistamines. Throughout the last decades, these drugs have been clearly differenti-
ated in first- and second-generation antihistamines.
First-generation antihistamines, such as chlorpheniramine, diphenhydramine, 
promethazine, and hydroxyzine, are characterized by their high H1 receptor blocking 
power, and in spite of their side-effect profile they are still widely used.7 One of their 
major downsides is their lack of selectivity for the H1 receptor as they are able to bind 
to acetylcholine and serotonin receptors and calcium channels.8 Furthermore, their 
lipophilic nature allows them to cross the blood–brain barrier, causing side-effects Journal of Asthma and Allergy 2009:2 74
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such as decreased alertness, impairment of reaction times, 
decreased vigilance, and sedation.9
Second-generation antihistamines, such as terfenadine, 
fexofenadine, loratadine, desloratadine, cetirizine, levo-
cetirizine, ebastine, rupatadine, and bilastine, do not 
penetrate the blood–brain barrier and so provoke minimal 
central nervous system (CNS) effects. They have greater 
receptor specificity, with little or no affinity for muscarinic 
cholinergic receptors. In addition, some second-generation 
antihistamines exhibit properties, such as anti-inflammatory 
and analgesic activity, on systems other than H1 receptors.7 
These properties and other pharmacochemical and pharma-
cokinetic differences among second-generation antihista-
mines are responsible for the emergence of the controversial 
term “third-generation” antihistamines for newer drugs.
Although second-generation antihistamines have been a 
clear step forward in the treatment of allergic diseases, they 
have not been devoid of problems. Cardiotoxicity has been 
a major issue, provoking the withdrawal of terfenadine and 
astemizole, for example, from the market10,11 and introduc-
ing the requirement of formal cardiac safety assessment in 
the drug development paradigm.12,13 Moreover, it has been 
demonstrated that some second generation antihistamines 
may cause somnolence,14 especially when used at supra-
therapeutic doses.9,15
In spite of the knowledge we have acquired over the past 
few decades, the search for the optimal antihistamine drug 
continues.16 Coined in 1990, the terms third-generation17 
or “multifunctional” antihistamines have been used laxly 
and inappropriately. As a result, in 2003, a consensus 
group on new-generation antihistamines (CONGA), led by 
Dr Holgate, provided recommendations on the development 
of new antihistamines.7
To date, no antihistamine drug has fulfilled all the criteria 
proposed by Holgate et al.7 However, some drugs, such as 
ebastine, appear to offer advantages that represent a step for-
ward in the development of these so-called third generation 
antihistamines.
In this review we look critically at the information 
available on ebastine in the light of the CONGA criteria 
and present current information on the development of new 
generation antihistamines.
CONGA recommendations
CONGA recommendations comprise 6 areas:
1.  Anti-inflammatory properties: A third-generation 
antihistamine should possess anti-allergic properties 
demonstrable in vivo, in humans, at therapeutic doses 
and under natural exposure to the offending allergens. 
It should be superior (in humans) to a comparator devoid 
of such properties. Nasal obstruction should be affected 
in a measurable way.
2.  Potency, efficacy, and effectiveness: The drug should 
have a high therapeutic index and differ radically from 
existing compounds.
3.  Lack of cardiotoxicity.
4.  Drug interactions: A third-generation antihistamine 
should not affect cytochrome P450 (CYP) isoenzyme 
function or be affected by it. This new drug should not 
displace protein bound medication and it should not 
affect active transportation mechanisms important in 
drug absorption and excretion.
5.  Lack of CNS effects: The minimum factors for classifying 
an antihistamine as “non-sedative” should include the 
study of incidence of subjective sleepiness, objective and 
psychomotor functions, and positron emission tomography 
(PET) measurement of H1-receptor occupancy.
6.  Pharmacological approach: The drug could be either 
an H1 blocker with an extra effect or a clean blocker 
of the H1 effects, having a special feature (eg, neutral 
antagonist).
Ebastine
Ebastine (4-diphenylmethoxy-1-[3-(4-terbutylbenzoyl) 
propyl] piperidine, Las-W-90, CAS 90729-43-4)18,19 is a 
long-acting, second-generation, selective H1-receptor inverse 
agonist, discovered and developed by Almirall SA. After 
over 18 years of use in more than 80 countries around the 
globe, the efficacy and safety of ebastine has been extensively 
demonstrated. Its clinical indications include the treatment 
of seasonal20–24 and perennial allergic rhinitis25,26 and chronic 
idiopathic urticaria.27,28 Small studies have found beneficial 
effects in patients suffering from allergic dermatitis, cold 
urticaria,29 dermographic urticaria,30 atopic asthma,30,31 
mosquito bites,32 and the common cold (in combination 
with pseudoephedrine).33 The pharmacology and the safety 
and efficacy profile of ebastine have been comprehensively 
reviewed.18,19,34,35 When administered in vivo, at least one of 
its metabolites, carebastine, also possess anti- H1 activity.36
Ebastine according to the CONGA 
recommendations
Anti-inflammatory properties
The efficacy of H1 antihistamines in allergic disorders 
has traditionally been attributed to their effects on the Journal of Asthma and Allergy 2009:2 75
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histamine receptor.8 The involvement of histamine in the 
allergic process has long been known, but as Thurmond 
et al37 recently suggested, its importance in modulating this 
reaction may have been underestimated. The allergic cascade 
is a complex response that is composed of three distinct 
immunological phases: sensitisation, early-phase allergic 
reaction and late-phase allergic reaction.38 Histamine’s role 
in this cascade comprises several cellular events involving 
the expression and/or release of cytokines, chemokines, 
adhesion molecules, and inflammatory mediators.39 These 
inflammatory mediators are modulated by H1 antihistamines, 
as has been demonstrated both in vitro and in vivo.40 While 
some authors postulate that these effects are independent 
of the H1 receptor,41–43 others relate them to H1 receptor 
blockade,44,45 although recent evidence has shown that both 
statements could be true.40
H1 receptor-dependent mechanisms involve stabiliza-
tion of the histamine receptor in its inactive conformation. 
Consequently, this stabilization inhibits generation of, 
globin transcription factor 3 (GATA-3), activator protein-1 
(AP-1) and nuclear factor κB (NF-κB).8,40 AP-1 and NF-κB 
are important transcription factors in inflammation. They 
regulate the expression of many pro-inflammatory mediators, 
such as CCL5/regulated upon transcription normal T cell 
expressed and secreted (RANTES), and play an important 
role in the pathogenesis of chronic inflammatory diseases 
such as asthma and allergy. Both are activated by the H1 
receptor in an agonist-dependent manner, and this activation 
is inhibited by various H1-receptor antihistamines.40,46
H1 receptor-independent mechanisms, however, inhibit 
histamine release from mast cells and basophils. They 
also inhibit inflammatory cell activation, and possibly 
eicosanoid generation and oxygen free radical production.8 
The inhibition of inflammatory cell activation comprises the 
downregulation of adhesion molecule expression, mediator 
release, superoxide generation, chemotaxis and cytokine 
expression, and the upregulation of the number and function 
of β2 adrenoceptors. The clinical relevance of this effect 
is still under discussion due to the fact that very high drug 
concentrations are needed and it is unlikely that these con-
centrations are achieved with therapeutic doses.
Modulation of adhesion molecule expression is important 
because molecules, such as inter-cellular adhesion molecule 1 
(ICAM-1) influence the activity of eosinophils, mast cells, 
macrophages and lymphocytes, all of which play key roles in 
the allergic reaction.8, 47 This modulating mechanism has been 
demonstrated in vitro and in vivo. In vitro, it has been shown 
that antihistamines reduce ICAM-1 expression on nasal and 
conjunctival epithelial cells, and it has also been observed 
that they reduce inflammatory infiltration after allergen 
challenge and during natural exposure. The mechanism 
underlying modulation of ICAM-1 is downregulation of the 
NF-κB transcription factor (that is necessary for adhesion 
molecule expression). Roumestan et al demonstrated that 
second generation H1 receptor antihistamines, mizolastine 
and desloratadine, inhibit NF-κB activity via two distinct 
pathways. One of these involves the H1 receptor (referred to 
earlier in this article), and the other is independent from this 
receptor. These authors also provided evidence that azelastine 
represses AP-1 activity via the same mechanisms.40
The inhibition of mediator release is another mechanism 
whereby antihistamines affect the allergic inflammatory reac-
tion, independently of their anti- H1 activity. In vitro studies 
have consistently established that H1 antihistamines inhibit 
the release of mediators from both mast cells and basophils. 
Nevertheless, these results are difficult to replicate in vivo 
as 3- or 4-fold therapeutic concentrations of antihistamines 
would be needed.8 As cytokines appear to contribute to the 
activation of basophils and eosinophils (chiefly interleukins 
[IL] 4 and 5) and the establishment and maintenance of aller-
gic inflammation, the effect of H1 antihistamines on cytokine 
secretion has also been studied with myriad compounds.
The inflammatory modulation of ebastine has been 
reported in various in vitro, and in vivo studies.31,36,48 
Campbell et al48 performed an in vitro study using dispersed 
cells obtained from surgically resected nasal polyps. They 
examined the effects of ebastine and carebastine on the 
release of leukotrienes C4/D4 [LTC4/D4] and prostaglandin 
D2 [PGD2]) after stimulation by anti-IgE and the spontane-
ous release of granulocyte macrophage colony stimulating 
factor [GM-CSF], tumour necrosis factor-α [TNF-α] and 
interleukin-8 [IL-8]. In vitro, ebastine and carebastine were 
shown to block the release of anti-IgE-induced eicosanoids 
LTC4/D4 and PGD2. Ebastine inhibited release of the two 
mediators by 30% at clinically relevant concentrations 
(IC30 = 2.57–9.6 µmol/L). Carebastine was less effective 
(IC30 = 8.14 µmol/L).
Campbell et al48 also performed a double blind crossover 
study (n = 12) to compare the effect of ebastine 10 and 20 mg 
once daily with that of placebo on the release of inflammatory 
mediators. In vivo, ebastine 20 mg induced an increase in the 
mean threshold number of pollen grains required to induce 
a positive response compared with placebo (P  0.003) and 
ebastine 10 mg (P  0.02). Ebastine was found to decrease 
the release of GM-CSF in a dose-dependent manner. It did 
not significantly alter the release of LTC4/D4 and PGD2 Journal of Asthma and Allergy 2009:2 76
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observed in most patients during the nasal provocation test 
and it did not affect cytokine release.
Regarding the secretion of cytokines, Nori et al evaluated 
the effect of ebastine on the production of T helper 2 (Th2) 
type cytokines. Using T cells derived from healthy non-atopic 
volunteers, they showed that ebastine inhibited the secretion 
in vitro of IL-4 and IL-5, but not that of IL-2 and interferon 
γ (IFNγ).49
Ebastine’s role in reducing airway inflammation has been 
suggested by Horiguchi et al31 who performed an open label 
study in which 20 patients with bronchial asthma (11 with 
atopic disease and 9 with nonatopic disease) received ebastine 
10 mg/day for 4 weeks. Serum eosinophil cationic protein 
(ECP) levels, peripheral blood eosinophil counts, morning 
peak expiratory flow rate (PEFR) and thresholds for airway 
hyper-responsiveness were determined before and after 
treatment. As a result, the atopic patients observed a decrease 
in serum ECP levels (from 25 ± 3 mg/L to 16.3 ± 2.4 mg/L; 
P  0.0014) and in peripheral blood eosinophil counts 
(from 468.2 ± 44.4/mm3 to 417.3 ± 47.8/mm3; P  0.0253). 
PEFR was significantly increased in the atopic patients 
(410.9 ± 16.1 L/min to 440 ± 19.1 L/min; P  0.0189). No 
changes were found in the nonatopic patients and there was no 
change in the threshold for airway hyper-responsiveness.
The results of another in vivo study by Ciprandi et al 
have been published recently.50 This group evaluated 
IFNγ production by peripheral blood mononuclear cells 
(PBMNC) using different stimuli in un-treated and treated 
(ebastine 20 mg) patients with persistent allergic rhinitis. 
Clinical changes were assessed by subjective (total nasal 
symptom score and visual analogue scales [VAS]) and 
objective (rhinomanometry) evaluations. The main result 
from this study was that IFNγ production stimulated by 
grasses and Dermatophagoides farinae was statistically 
increased (P  0.0001 and P  0.0015 respectively) in 
patients receiving ebastine.
Nasal obstruction is the leading symptom in patients with 
allergic rhinitis, with allergic inflammation, mucosal conges-
tion and mucus hypersecretion playing key roles.51 CONGA 
recommendations suggest that nasal obstruction should 
be affected in a measurable way by newer antihistamines. 
The decongestant activity of ebastine was first suggested 
by Ratner et al52 after they performed 3 double-blind, 
randomized, placebo-controlled, parallel group studies that 
compared ebastine 20 mg, ebastine 10 mg, loratadine 10 mg 
and placebo in the control of symptoms of ragweed-induced 
rhinitis. Although the results showed that ebastine at both 
doses reduced nasal congestion as compared to placebo, nasal 
congestion was measured subjectively (ie nasal congestion 
symptom scores). The effect of ebastine on nasal obstruction 
was further evaluated in a pilot study (n = 20) by Ciprandi 
et al.53 These authors evaluated nasal symptoms (rhinorrhea, 
itching, sneezing and obstruction), nasal airflow (by means 
of rhinomanometry) and the response to a decongestion 
test with naphazoline 1 mg/mL in patients with persistent 
allergic rhinitis before and after 3 weeks of treatment with 
ebastine 20 mg/day. Results were positive and showed that 
ebastine induced symptom relief as assessed by compar-
ing basal nasal symptom total scores with post-treatment 
scores (P = 0.0013). Ebastine also increased nasal airflow 
(P = 0.0001) and in the decongestion test the percentage of 
reversibility diminished significantly from baseline (111%) 
to post ebastine treatment (46%, P = 0.0003). Although a 
double-blind, randomized controlled trial with active com-
parators and placebo would be the most suitable design to 
obtain conclusive evidence, this pilot study showed that nasal 
obstruction can be affected in a positive way by antihistamine 
treatment with ebastine.
Presently available evidence indicates that some second 
generation antihistamines possess properties that modulate 
the allergic inflammatory cascade by means of H1 receptor 
dependent and independent mechanisms. All in all, in vitro, 
in vivo and clinical studies using subjective and objective 
measurements seem to indicate that ebastine possesses this 
characteristic and ameliorates nasal congestion to some degree. 
However, to clarify this effect a clinical trial including a 
comparator devoid of modulator effect should be carried out. 
Until this piece of the puzzle is put in place we can not conclu-
sively claim that ebastine complies with the first requirement 
exposed in the CONGA. Including more than one comparator 
in future studies would be especially useful as it would provide 
further information that could help to elucidate the allergic/
inflammation pathways that each antihistamine involves.
Potency, efficacy, and effectiveness
Ebastine was initially conceptualized as the combination 
of the structural elements of the very potent, yet sedative 
antihistamine, diphenyl-pyraline and the less potent, but 
nonsedative, terfenadine.16
The receptor-binding affinity and receptor-dissociation 
rate for antihistamines on peripheral H1 receptors help 
to better characterize novel anti-H1 receptor drugs. They 
also allow an appraisal of the likely in vitro potency at the 
H1 receptor in relationship to known standards, and provide 
potential information on duration of action.54 The H1 receptor 
affinities for ebastine and carebastine are 48 ± 6 nM and Journal of Asthma and Allergy 2009:2 77
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27 ± 4 nM, respectively, while two other minor metabolites 
also have good H1 receptor affinity (HO-ebastine and 
diphenyl-norpyraline).55
The binding characteristics of an H1 receptor antihis-
tamine determine the extent to which histamine can be 
blocked from binding to the H1 receptor. These binding 
characteristics are an integral component for the efficacy and 
safety of an antihistamine. However, specific characteristics 
of an H1 receptor antihistamine may influence its potency, 
and high in vitro H1 binding activity does not necessarily 
imply good clinical efficacy because many other factors 
(such as uptake, metabolism, and pharmacokinetics) are 
also relevant. Moreover, some H1 receptor antihistamines 
may lack specificity and bind to other receptors, causing 
unwanted side effects.38
Ebastine has a potent and selective H1 antihistamine activity, 
as assessed by in vitro and in vivo studies. Contrary to the prop-
erties of other antihistamines, the anticholinergic and anti-sero-
tonergic properties of ebastine have proved to be negligible.56 
Ebastine and carebastine show a weak affinity for the 5-HT2 
receptor, and they do not bind to adrenergic α1, dopaminergic 
D2, benzodiazepine, muscarinic, cholecystokinin, N-methyl-
D-aspartatic acid (NMDA), calcitonin gene-related peptide 
(CGRP), neuropeptide Y, neurotensin, opiate, somatostatin, 
NK1, vasopressin V1, vasoactive intestinal peptide (VIP), bra-
dykinin B2, or Ca++ channels.55
In vitro potency has been demonstrated in a series of 
experiments performed by Almirall. Their results showed 
that ebastine inhibits histamine-induced contractions in an 
isolated ileum model. In a competitive antagonism assay, 
they found that the negative logarithm of the concentration 
(mol/L) of antagonist which would produce a 2-fold shift in 
the concentration-response curve for an H1 agonist (pA2) was 
7.9 for ebastine and 8.7 for carebastine.36 When acetylcho-
line was used as the agonist, the ED50 value of ebastine was 
greater than 30 mg, sustaining the almost null anticholinergic 
effect. In a noncompetitive antagonism assay the negative 
logarithm of the concentration (mL/L) required to reduce 
the maximum response to an H1 agonist by half (pD2) was 
5.8 for ebastine, showing ebastine was at least 100 times less 
potent as an “atropine-like” muscarinic antagonist than as an 
antihistamine.36 In addition to this isolated ileum model, an 
in vitro study in tracheally perfused guinea pig lungs provided 
evidence that ebastine inhibits bronchoconstriction induced 
by leukotriene C4.56
Potency in vivo has mainly been studied in guinea pigs. 
It has been observed that ebastine causes a dose-related 
inhibition of histamine-induced bronchospasm with an 
ED50 value of 170 µg/kg po (80 µg/kg for carebastine) in 
comparison to terfenadine that required 780 µg/kg.36 Llupia 
et al reported that ebastine had a ED50 115 µg/kg po against 
aerosol histamine-induced bronchospasm in guinea pigs. 
They also found that ebastine was a potent compound in 
inhibiting allergen-induced bronchospasm in conscious 
guinea pigs (ED50 334 µg/kg po). In another in vivo study, 
ebastine reversed the changes in pulmonary resistance 
induced by leukotriene C4 in anesthetized guinea pigs, 
whereas cetirizine and loratadine were devoid of activity in 
this model.56
Potency in humans can be assessed by evaluating distinct 
biomarkers that may be related to histamine activity. Examples 
of biomarkers in this setting are the wheal and flare response 
after a skin-prick test, the measurement of inflammatory 
mediators after nasal challenge with histamine or allergens, 
and the inhibition of histamine-induced brochospasm.54
The histamine wheal-and-flare response provides 
information on the preliminary efficacy of the H1 receptor 
antihistamine following oral dosing and has been widely 
used. It is sometimes criticized, however, because it does 
not mimic the late phase response of the allergic process, 
mast cell degranulation, and inflammatory mediator release. 
It has also been stated that it does not correlate with results 
in patients.38 Speed of onset of activity, magnitude of effect 
and duration of action can be assessed, as with skin-prick 
test studies, with nasal applications studies, using single-dose 
histamine challenges at repeated time points.
Ebastine at doses 10 mg significantly reduced the 
histamine-induced cutaneous wheal response in healthy 
adult volunteers and in adult patients with allergic rhinitis 
in comparison with placebo.19 Studies have shown that the 
reduction in wheal size is significantly greater with ebastine 
10 mg than with placebo after intradermal histamine chal-
lenge (P  0.001). This reduction reaches its peak around 
6 to 12 hours after drug administration. In children, ebastine 
5 and 10 mg has shown to reduce histamine-induced wheal 
and flare compared with baseline values for up to 28 hours. 
Overall, ebastine 10 mg has shown to be as effective at 
inhibiting the histamine-induced wheal response as several 
other antihistamines, whilst ebastine 20 mg proved to be 
more effective than others (eg, loratadine, cetirizine, and 
fexofenadine).19,57–59
The effect of ebastine has been also assessed by cuta-
neous and nasal challenge with allergens, and through the 
measurement of inflammatory mediators. One study aimed 
to determine the time period required for the inhibitory effect 
of ebastine on allergen-induced skin reactivity to disappear Journal of Asthma and Allergy 2009:2 78
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completely, and recruited patients (n = 23) with an allergy 
to house dust mite, cat dander, a mixture of 5 grass pollens, 
or birch pollen. After 7 days’ treatment with ebastine 20 mg, 
skin prick tests with allergens revealed a highly significant 
(P  0.01) inhibition of the wheal surface area at 6 hours, 
24 hours, and 2 days after treatment compared with placebo. 
The inhibitory effect of ebastine on wheal disappeared by 
day 4 after discontinuing treatment, and the effect on flare 
by day 3. A marked inhibitory effect of ebastine was seen on 
the histamine-induced wheal surface area at 6 and 24 hours 
after treatment completion compared to placebo. There was 
no residual effect of ebastine compared to placebo 5 days 
after treatment discontinuation.19,60 Additionally, in grass 
pollen allergic patients (n = 12), van Steekelenburg et al 
compared 5 second generation antihistamines by assessing 
eosinophilia in nasal smears, histamine/grass pollen skin 
tests and grass pollen nasal provocation tests. In patients with 
grass pollen allergy, ebastine 10 mg reduced the diameter of 
grass pollen-induced wheals at 4 and 8 hours postdosing to 
a significantly greater extent than placebo (P = 0.013) and 
to a similar extent to other antihistamines such as loratadine 
10 mg, cetirizine 10 mg, fexofenadine 120 mg, and mizo-
lastine 10 mg.19,61
The effect on inflammatory mediators has also been 
tested. As assessed by Campbell et al48 (see section above), 
mean percent inhibition provoked by ebastine on mediator 
release from human dispersed nasal polyp cells was 50% 
for PGD2, 33% for LTC4/D4, 40% for tumor necrosis 
factor-α (TNF-α), 35% for GM-CSF, and 52% for IL-8, 
compared to placebo (all P  0.05).
Antonijoan  et al  performed  two  double-blind, 
double-dummy, randomized, placebo-controlled, 3-period 
crossover clinical trials14,62 to assess the pharmacodynamics 
of a fast-dissolving tablet (FDT) of ebastine. This relatively 
new formulation facilitates administration to patients who 
have problems swallowing tablets and hard gelatine capsules, 
such as geriatric patients and those who are ill in bed or 
those who may not have access to water to aid swallowing. 
In these studies ebastine (10 mg in the first and 20 mg in 
the second study) was compared with desloratadine 5 mg or 
placebo. Besides assessing the inhibition of wheal response 
to cutaneous histamine challenge using a histamine skin-
prick test, both included subjective assessments of itching, 
flare and pain by means of VAS, tolerability assessments, as 
well as acceptability and convenience evaluation, measured 
by a questionnaire. The main outcome was inhibition of 
the response to the histamine challenge, defined as the 
percentage reduction from baseline in the wheal area of the 
skin intradermal test conducted 24 hours after the fifth dose 
of study medication.
In the first trial62 (FDT ebastine 10 mg), the mean percent-
age reduction from baseline in the wheal area 24 hours after 
completion of 5 days’ treatment was significantly greater with 
ebastine than with desloratadine and placebo (44.6% vs 17.9% 
and –2.3%, respectively; both P  0.0001). Mean differences 
in reduction from baseline to 24 hours after 5 days of treat-
ment in the wheal area were 26% for FDT ebastine 10 mg vs 
desloratadine 5 mg and 46.9% for ebastine vs placebo (both, 
P  0.0001). In the second trial14 (FDT ebastine 20 mg), 
the mean percentage reduction from baseline in wheal area 
24 hours after 5 days of treatment was significantly greater 
with ebastine compared with desloratadine, and placebo 
(55.8% vs 26.8% and 12.2%, respectively; both P  0.001). 
Mean differences in reduction from baseline in the wheal 
area were 29% for ebastine 20 mg vs desloratadine 5 mg, and 
43.7% for ebastine vs placebo (both, P  0.001).
These studies showed that, after 5 days of administration, 
inhibition of the response to histamine injection was signifi-
cantly greater with FDT ebastine 10 and 20 mg than with 
desloratadine 5 mg. As denoted by the authors, this test does 
not necessarily correlate with clinical responses. However, 
it is important to assess and compare the pharmacodynamic 
effects of antihistamines.14,62
Concerning the therapeutic index, evidence supports the 
notion that ebastine has a wide therapeutic index. In phar-
macological safety models, ebastine showed no central 
nervous system effects and did not affect heart rate or blood 
pressure in conscious rats and dogs at doses up to 100 mg/kg 
(ie, 600 times the therapeutic dose).63
The toxicology profile also showed that ebastine is free of 
toxic effects in animals, even at doses representing extremely 
high multiples of the recommended therapeutic dose in 
humans (0.17 mg/kg).36 In fact, since the lethal dose 50% 
(LD50) was impossible to calculate, the therapeutic safety 
ratio (LD50/ED50) of ebastine is more than 20000.36
As well as all of the pharmacodynamic characteristics 
described above, ebastine has shown to be effective for the 
relief of symptoms in adults and adolescents with allergic 
rhinitis or chronic idiopathic urticaria. The efficacy of 
ebastine for the treatment of seasonal and perennial allergic 
rhinitis has been evaluated in five pivotal trials20,25,26,64–66 and 
several supporting trials.22,23,67–70 Pivotal trials enrolled a total 
of 1394 patients (685 in the seasonal allergic rhinitis studies 
and 709 in the perennial allergic rhinitis). Four of the trials 
lasted 3 weeks and the other lasted 12 weeks. The goal was 
to show superiority of ebastine over placebo. Ebastine 10 and Journal of Asthma and Allergy 2009:2 79
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20 mg were used. The primary goal of the comparative 
efficacy in supporting studies was to show the superiority 
of ebastine over other H1 receptor antihistamines.55 In most 
trials, the evaluation of efficacy was based on the assessment 
of nasal symptoms (rhinorrhea, sneezing, itching and obstruc-
tion) and ocular symptoms (eg itch, discharge, conjunctivitis). 
Symptoms were assessed individually and/or as composite 
scores such as total symptom score, nasal index (a composite 
of 4 nasal symptoms) or perennial index (nasal symptoms 
excluding obstruction).19
Overall, ebastine has shown superiority over placebo 
in the treatment of seasonal and perennial allergic rhinitis 
and ebastine 10 mg has shown to be at least as effective as 
loratadine 10 mg and cetirizine 10 mg at reducing symptoms 
in patients with allergic rhinitis, whereas ebastine 20 mg 
was generally more effective than the comparator antihista-
mines at the used dosages.19,55 In contrast with the differences 
detected when using the skin wheal and flare test, few clinical 
differences were observed among the different antihistamines 
when the allergic rhinitis model was used.71
For chronic idiopathic urticaria, the efficacy of ebas-
tine has been evaluated in 2 randomized, double-blind, 
controlled trials, one compared to placebo28,72 and the other 
to terfenadine and placebo.28 Efficacy evaluations included 
change from baseline in symptoms and global evaluation 
of efficacy by patients and physicians. Ebastine 10 mg was 
significantly more effective than placebo at reducing the 
symptoms of urticaria (P  0.001)28,72 and was similar to 
terfenadine 60 mg twice daily.28
Effectiveness, or H1 antihistamine activity in the real 
world, as expressed by patients’ willingness to use a specific 
H1 antihistamine, has been extensively studied for the FDT 
formulation of ebastine.73–78 Roger et al73 performed a 
clinical study in which they assessed qualitative face-to-face 
interviews with physicians and allergy patients in order to 
understand the key attributes of the FDT formulation of 
ebastine (a placebo sample was used). The key attributes were 
convenience, ease of use, and perception of faster onset of 
action. Moreover, most patients (75%) expressed that the FDT 
formulation would improve compliance, and the likelihood of 
taking/prescribing this formulation was ranked high both by 
patients and physicians (6 to 8.8 for patients and 7.4 to 8.1 for 
physicians on a 1 to 10 scale). Ebastine FDT has also been 
rated better by patients for general assessment, texture, initial 
taste, after taste and sensation on dissolving.75 This has been 
further proved by a quantitative, descriptive, cross-sectional 
opinion study in which pharmacists answered a structured 
questionnaire after evaluating the experience referred by 
clients who had tried the ebastine FDT formulation. Ebas-
tine FDT was conveniently rated for time to dissolving and 
sensation on dissolving (4.35 [SD 0.95] and 4.03 [SD 0.92] 
respectively).78
All the above-mentioned characteristics are examples 
of desirable properties in third-generation antihistamines. 
Notwithstanding, ebastine does not show a radically different 
profile from existing compounds that would allow its 
denomination as a third-generation antihistamine.
Lack of cardiotoxicity
In the mid 1990s, some second generation H1 antihistamines 
were associated with prolongation of the QT interval and 
the development of fatal arrhythmias such as torsade de 
pointes.79,80 Two second-generation antihistamines, terfena-
dine and astemizole (both now withdrawn from the market), 
block the rapid component of the delayed rectifier potassium 
current (IKr). As a result, these drugs potentially prolong 
the monophasic cardiac action potential and QT interval, 
induce the development of early after-depolarizations and 
dispersion of repolarization, and may thereby cause torsade 
de pointes.39 It is noteworthy that these events are mostly 
associated with high plasma concentrations due to overdose 
or co-administration with other drugs that inhibit their metab-
olism via hepatic microsomal enzymes (such as CYP3A4). 
Moreover, cardiac toxic effects induced by H1 antihistamines 
are rare as they occur independently of the H1 receptor and 
are not a class effect.10,39,81
The withdrawal of terfenadine and astemizole, along 
with other drugs that have proven to be cardiotoxic, has 
brought cardiac safety in the drug development process to 
the forefront of regulatory medicine. Since 1997, regulatory 
guidelines have been available, emphasizing the strategy 
for assessing the propensity of new (nonantiarrhythmic) 
medicinal products to prolong the QT interval. The first 
of these was issued by the EU Committee for Proprietary 
Medicinal Products (CPMP). It included recommenda-
tions for the design of clinical and nonclinical testing in 
order to assess the cardiac safety profile of new chemical 
entities (NCEs).
In 2002, the US Food and Drug Administration (FDA) 
and Health Canada (HC) issued a joint preliminary concept 
paper on clinical strategies for evaluating the effects of 
NCEs on QT/QTc interval prolongation. This paper was later 
adopted by the International Conference on Harmonization 
(ICH) for global implementation as ICH topic E14 and 
published simultaneously with ICH topic S7B, which is 
primarily concerned with the nonclinical investigation of the Journal of Asthma and Allergy 2009:2 80
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effects of new drugs on cardiac repolarization. Approved in 
2005, ICH E14 is concerned mainly with the design, conduct, 
analysis, and interpretation of clinical studies to assess the 
potential of a drug to delay cardiac repolarization. The main 
tool proposed to meet this goal is the “thorough QT/QTc 
study”. Design is central to this study as it should be random-
ized and double-blind, and should involve the concurrent 
use of both a placebo control group and a positive control 
group (pharmacological or nonpharmacological) to establish 
assay sensitivity. Whenever possible this study should be 
crossover. To address intrinsic variability in the conduct 
of the thorough QT/QTc study, the collection of multiple 
electrocardiograms (ECGs) at baseline and during the study 
is strongly recommended. Moreover, the examination of 
concentrations that are higher than those achieved following 
the anticipated therapeutic doses is also deemed necessary. 
Reliability is further enhanced by digitally obtained ECG 
recordings, electronic transmission and central collection 
for measurement.13
Ebastine and its main active metabolite, carebastine, have 
been exhaustively evaluated for potential effects on cardiac 
repolarization.82 Ebastine shares some structural features with 
terfenadine and it is able to interact with potassium channels. 
Some years ago this gave rise, to concerns about its possible 
cardiotoxic effects. Such concerns have now been addressed 
and discarded following results from experimental models 
both in animals and in the clinical setting. Ebastine either 
has no deleterious cardiac effects or shows only small and 
non-clinically significant effects at this level. One possible 
explanation for its increased H1 receptor activity and its 
almost null cardiotoxicity in comparison with terfenadine 
is that subtle modifications in structure not only make ebas-
tine nonchiral but also determine the acquisition of a folded 
3-dimensional conformation, as opposed to the extended 
conformation of terfenadine. The modifications in structure 
consist of the replacement of the alcoholic hydroxyl group by 
a ketone oxygen and the introduction of an ether link between 
the diphenyl-methyl moiety and the piperidine ring.16,83
In vitro, the electrophysiological effects of ebastine and 
carebastine have been studied in isolated rabbit Purkinje 
fibers. In normal and low potassium solutions (4 mM and 
2.7 mM K+) ebastine (at a concentration of 1 nM to 1 µM) and 
carebastine (at a concentration of 1 nM to 1 µM) produced 
a concentration-dependent prolongation of action potential 
duration (APD) without impairment of the maximum rate 
of depolarization.55
Ko et al84 performed a study on suppression of potassium 
channels by ebastine, utilizing the whole cell patch-clamp 
technique. The IKr channel (delayed rectifying rapid) was 
examined in both the human Ether-à-go-go Related Gene 
(HERG)-expressing × laevis oocytes and guinea pig ven-
tricular myocytes; the IKs (delayed rectifying low) and the IKl 
(inward rectifying) were studied in the guinea pig ventricular 
myocytes and the Ito (transient outward) and the IKped (rapidly 
activating delayed rectifier) were studied in the rat heart. This 
study showed that ebastine had significant suppressive effects 
on the IKr, IKs and IKped channels, but it was less effective in 
blocking the Ito and IKl. These results have been challenged 
in the past for quoting values for 50% inhibition of the maxi-
mum inhibition and not 50% of complete inhibition.55
Almirall performed studies transferring hERG channels 
to human embryonic kidney (HEK-293) cells. They compared 
ebastine to terfenadine and loratadine and calculated the IC50. 
The results were 331 nM for ebastine, 208 nM for terfenadine 
and 200 nM for loratadine. With these data they concluded 
that ebastine is the least likely of the antihistamines tested 
to affect hERG channels.55
In vivo animal evidence concerning the effect of ebas-
tine on cardiac conduction was controversial for many years. 
One of the in vivo models used to assess ebastine effects was 
the corrected QT (QTc) interval prolongation following drug 
administration to anesthetized guinea pigs.85 Hey et al86–89 
(working for Schering-Plough Research Inc., US marketer of 
loratadine) showed that intravenously administered ebastine 
(3 to 50 mg/kg) caused dose-related prolongation of QTc in 
anesthetized guinea pigs in a manner comparable to that seen 
with terfenadine (1 to 10 mg/kg). This group also showed 
accentuation of QTc prolongation by ebastine (10 mg po, 
approximately 20 mg/kg) in conscious guinea pigs pretreated 
with ketoconazole (200 mg po, approximately 400 mg/kg). 
Gras et al90,91 (employees at Almirall, marketer of ebastine) 
provided contradictory evidence of the dose-related prolon-
gation of QTc. Ebastine showed no significant prolonging 
effect on the QTc interval, even when administered at a 
dose almost 120 times higher than the corresponding dose 
of terfenadine. In another study the same group found no 
interaction between ebastine (20 mg po) and ketoconazole 
(400 mg/kg) administered to conscious guinea pigs, although 
it should be pointed out that the positive control, terfenadine, 
was also negative.55
In anesthetized dogs intracoronary infusion of ebastine 
(30 µg/min for 1 hour) was not associated with an increase 
in electrocardiographic QTc intervals that predisposed to 
ventricular arrhythmias.36,82
In another in vivo study in rats differences in accumula-
tion of antihistamines into cardiac tissue were addressed. Journal of Asthma and Allergy 2009:2 81
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Animals were administered antihistamines orally for 5 days 
at a dose calculated to achieve steady state concentrations 
substantially higher than in humans. The authors determined 
the ratio between the hERG IC50 and the plasma level of 
the free compound at steady state Cmax (µM) and the ratio 
between the hERG IC50 and the Cmax in the rat heart at steady 
state. High ratios of ebastine and carebastine suggested that 
the putative arrhythmogenic potential of ebastine was lower 
than that of terfenadine.55
From the clinical point of view, the cardiac safety of 
ebastine has been evaluated in several studies. While some of 
them were specifically designed for this purpose, some others 
were pharmacokinetic–pharmacodynamic drug interaction 
studies. Additionally, placebo-controlled efficacy studies, 
comparative efficacy studies, and studies in special popula-
tions have been performed.
Several cardiac safety studies have been conducted. Firstly, 
Gillen et al92 performed a 4-way crossover study to compare the 
effect of high doses of ebastine with terfenadine and placebo 
on QTc. Three and 5-fold the maximum recommended dose 
of ebastine (ie, 60 and 100 mg, once daily) and three-fold the 
maximum recommended dose of terfenadine (ie, 180 mg bid) 
or placebo were administered for 7 days. QT was corrected fol-
lowing both the Bazett and Friedericia corrections. According 
to the results of this trial, ebastine 60 mg did not significantly 
alter any QTc, vs placebo. Nevertheless, ebastine 100 mg 
produced a statistically significant prolongation of QTc accord-
ing to Bazett’s correction. In any case, the QTc increase after 
ebastine 100 mg was significantly less than with terfenadine 
(+10.3 ms vs +18.0 ms, P  0.05). Noteworthy is that the 
authors interpreted that they “overcorrected” the QT interval 
using Bazett’s correction. Since then, Malik93 has argued that 
measuring imprecision and natural variability can lead to 
mean QTc interval changes of 4 to 5 msec in the absence of 
drug treatment. He also stated that use of published heart rate 
correction formulas in the assessment of drug-induced QTc 
prolongation is inappropriate and that correction formulas 
optimized for pooled drug-free data are inferior to the formulas 
individualized for each subject.93
Later, a randomized, double-blind, placebo controlled 
parallel group study compared the electrocardiographic 
effect of ebastine 10, 20, 40 (in one randomization schedule) 
and 80 mg qd (in a second randomization schedule) with 
placebo for 9 days in healthy volunteers. The relationship 
between QTc prolongation and plasma ebastine/carebastine 
concentrations was also explored. Primary analysis comprised 
the change from baseline QTc measurements, according to 
Bazett’s method. In this study, ebastine 10, 20, and 40 mg 
caused a dose-dependent prolongation of QTc, corrected by 
Bazett’s or Friedericia’s formulae. As individual QT variation 
was very large, no post-hoc analyses of QTc by other meth-
odology could be carried out.55
In another attempt to explore the relationship between 
QTc prolongation and ebastine administration, an open-label, 
placebo-controlled, single ascending dose study was per-
formed with doses of 80, 150, 300, and 500 mg in 6 healthy 
male volunteers. Increases in heart rate and QTc, corrected 
by Bazett’s or Friedericia’s method, were dose-proportional, 
but no single QTc interval was greater than 500 msec, and no 
intra-individual postdose increase in the mean QTc interval 
was greater than 10%. The interpretation of these results was 
limited by the reduced sample size number.55,94
Various drug-interaction cardiac safety studies have been 
carried out. Chiefly, the risk of interaction between ebastine 
and erythromycin (2 studies) or ketoconazole (3 studies) 
has been evaluated.82,95 Two additional studies were aimed 
at comparing the interaction of loratadine and ketoconazole 
with the interaction of ebastine and ketoconazole.55
One study (n = 15) comprised multiple-dose admin-
istration of erythromycin stearate 500 mg every 6 hours 
on days 4 through 12 with single-dose ebastine 20 mg 
in the morning of days 1 and 9. Holter monitoring and 
telemetry showed no clinically relevant changes in QTc 
interval or cardiac parameters in spite of evident pharma-
cokinetic interaction between ebastine and erythromycin.55 
Nonetheless, in a separate crossover study (n = 30), 
the co-administration of multiple-dose ebastine 20 mg 
qd with erythromycin ethylsuccinate 800 mg tid for 
10 days produced a statistically significant prolongation 
of QTc interval (10 ms); no clinically significant changes 
occurred, however.82 In comparison to the Cmax and AUC0–24 
achieved with ebastine plus placebo, when ebastine 
plus erythromycin was administered there was a 2-fold 
increase in the Cmax and a 3-fold increase in the AUC0–24 
of ebastine. Additionally there was a 2-fold increase in the 
Cmax and 2.5-fold increase in the AUC0–24 of carebastine. 
After treatment, the difference for ebastine plus erythro-
mycin over placebo plus erythromycin for QTc according 
to Bazett’s correction (QTcB) was 10.7 msec. The uncor-
rected comparison was –2.8 msec. Post-hoc analyses did 
not change overall findings.55,82
Assessment of the interaction of a single dose of ebas-
tine 20 mg combined with multiple doses of ketoconazole 
400 mg qd on days 4 through 12 (n = 12) produced no clini-
cally relevant changes in cardiac parameters in healthy male 
volunteers.55,82Journal of Asthma and Allergy 2009:2 82
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In a blinded, parallel group, placebo-controlled multiple 
dose study (n = 55), ebastine 20 mg qd or placebo were admin-
istered for 5 days and ketoconazole 400 mg qd was added to 
that treatment for an additional 8 days. In the ebastine plus 
ketoconazole group the maximum plasma concentrations 
(Cmax) of ebastine were 15-fold higher than placebo, the mini-
mum plasma concentrations (Cmin) were 70-fold higher and 
the area under the plasma concentration-time curve (AUC0–24) 
was 40-fold higher.55,82 Initial analysis showed that the addition 
of 8 days of ketoconazole to ebastine at a steady state caused 
a 18.1 ± 2.5 msec prolongation in the mean QTcB com-
pared to an 8.0 ± 2.3 msec prolongation for the placebo plus 
ketoconazole combination (P  0.0023). Post-hoc analyses 
with other QTc correction formulae (Friedericia, Malik and 
linear regression analysis) did not sizably modify results.55 
Data were later analyzed correcting QT for heart rate (QTc) 
using the parabolic log/log formula (QTc = QT/RRα; α = 0.25 
for Kawataki, 0.31 for Yoshinaga, 0.32 for Simonson, 0.33 for 
Fridericia, 0.38 for Hodges, 0.398 for Boudolas, 0.5 for Bazett 
and 0.603 for Mayeda), but individualized α values derived 
from individual off-drug QT/RR relationships were used for 
each subject. Chaikin et al95 argued that this avoids the prob-
lem of using formulae based on populations other than that 
under study, and allows for considerable interindividual vari-
ability in QT/RR relationships, but intraindividual variability 
over time is low. Using this approach, no changes in cardiac 
repolarization were evidenced by the absence of statistically 
significant changes in the increase of the mean QTc in the 
ketoconazole/placebo group (6.96 [95% CI 3.31 to 10.62] ms) 
compared with ketoconazole/ebastine (12.21 [95% CI 7.39 to 
17.03] ms; P = 0.08).95
A pivotal drug interaction cardiac safety study was 
designed with the input of the FDA and was the first of its kind 
to include women.55 An individual QT correction factor was 
determined at baseline and used throughout the study. This 
methodology was deemed satisfactory considering the high 
inter and intra-individual variability of QT. This multiple dose 
ebastine and ketoconazole interaction study had a 2-period 
crossover design. Ebastine 20 mg q.d. was administered 
for 13 days and ketoconazole 400 mg qd or placebo was 
added on the last 8 days. The addition of ketoconazole 
caused a significant increase of 16-fold in Cmax, 44-fold in 
AUC0–23.5 and 52-fold AUC0–∞ of ebastine. For carebastine, 
only the AUC0–∞ was significantly increased. Ketoconazole 
increased the resting heart rate on day 13 by 4.6 msec over 
baseline compared to placebo and provoked a statistically 
significant (+11.9 ms vs 0.38 msec mean QTc; difference 
10.71 msec; P = 0.0000) interval prolongation compared 
to placebo (using Malik correction formula [QTcM]). This 
held true when using other correction formulae. Using 
pharmacokinetic/pharmacodynamic regression analysis, 
it was demonstrated that there was a plateau effect for prolon-
gation of QTc at 10.71 msec. This suggests that if exposure 
increased above that observed in this study, the QTc would not 
be further prolonged. The FDA later challenged these results 
and considered that goodness of fit analysis did not support 
a single exposure-response QTc model due to the limitations 
inherent to inter- and intra-subject variability.
Results from studies comparing ebastine plus ketocon-
azole with loratadine plus ketoconazole pointed in the same 
direction. The mean QTcB change with the administration 
of ketoconazole was 16.5 for ebastine and 11.3 for loratadine 
in the first study. In the second study the mean QTcB change 
was 16.3 for ebastine and 9.6 for loratadine. Differences were 
of lesser magnitude using Marek Malik’s correction.55
Pooled data from high-dose ebastine studies and drug 
interaction studies, particularly studies investigating the 
interaction between ebastine and ketoconazole, showed a 
positive relationship between increasing ebastine plasma 
concentrations and QTc interval changes. In contrast with 
findings using terfenadine, the QTc interval-plasma concen-
tration curve reached a plateau at low level of QTc prolonga-
tion (10 msec) despite large, progressive increases in blood 
concentrations of ebastine and carebastine.82,96
During the placebo-controlled efficacy studies, ECGs 
were performed at baseline and weekly, at 3 to 5 hours after 
dosing (around the approximated Tmax for ebastine). Baseline 
and double-blind ECG evaluations were performed in a total 
of 1202 patients. Moreover, Holter monitoring was performed 
in a subset of patients in these studies (n = 226). A dose-
dependent increase of QTc outliers was seen, suggesting 
that ebastine prolonged QTc in some patients, although no 
clinically relevant changes were seen on Holter monitoring.55 
As opposed to placebo-controlled studies, comparative 
efficacy studies did not include Holter monitoring. With the 
exception of a few outliers, no definitive statements about 
cardiac safety could be made.55
The pharmacokinetics of ebastine have been investigated 
in several special situations. Evidence has emerged from a 
food interaction study, and from studies in patients with renal 
failure97 and liver failure,98 and in children82 and elderly vol-
unteers. In the food interaction study a single dose of ebastine 
10 or 20 mg with and without food produced no clinically 
relevant electrocardiographic effects, despite the fact that 
exposure to carebastine was 50% higher with food than with-
out.82 No clinically relevant ECG findings have been observed Journal of Asthma and Allergy 2009:2 83
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in patients with renal failure,97 liver failure,98 or children.82 
The electrocardiographic effect of ebastine in the clinical set-
ting was studied by Huang et al.99 These authors performed a 
randomized, double-blind, multiple-dose, placebo-controlled, 
parallel group study in healthy young and elderly volunteers. 
Twelve-lead electrocardiography was performed before dos-
ing and repeated 4 hours after dosing on days 1, 5, and 10. 
Additionally, 24-hour Holter monitoring was performed after 
10 days of treatment with ebastine 10 mg or placebo. The 
results showed no clinically significant abnormalities either 
in young or in elderly volunteers.
Undoubtedly, the most difficult and contentious issue fac-
ing ebastine has been proving its cardiac safety. Ebastine was 
first marketed in Spain in 1990 and in 1998 the first New Drug 
Application (NDA) submission was filed by Rhône-Poulenc 
Rorer, Almirall’s strategic partner at that time. Because of 
cardiac safety concerns and significant pharmacokinetic 
interactions with drugs metabolized by CYP3A4 that resulted 
in increased plasma concentrations and potential QTc interval 
prolongation, the FDA decided not to approve ebastine for 
marketing in the US on March 23, 1999.55 Three years later, 
in 2002, Almirall resubmitted an NDA for ebastine. They 
provided new clinical evidence of its safety and argued that 
Bazett’s method for QT correction tended to overcorrect the 
QTc interval when heart rate is increased. Ebastine’s cardiac 
safety has been assessed differently by different regulatory 
bodies around the globe. Ebastine is currently marketed in 
over 80 countries and there have been no reports of fatal 
arrhythmias linked to its use. Nevertheless, caution is war-
ranted in patients with a long QT interval, in those who are 
on drugs that affect the P450 cytochrome system, and in 
patients with hypokalemia.
In retrospection, a thorough QT/QTc study with a concur-
rent positive control would have provided valuable informa-
tion on the cardiac safety of ebastine and would possibly have 
eliminated the need for further studies. No such study was 
performed for ebastine as guidelines for QT/ QTc studies 
were not published until 2005. A thorough QT/QTc study 
provides very reliable information, as the subjects serve as 
their own controls and hence reduce differences related to 
inter-subject variability. In addition, the thorough QT/QTc 
study design facilitates heart rate correction approaches based 
on individual subject data.13
Drug interactions
The interactions described to date between H1 antihistamines 
and other drugs or substances fundamentally take place 
via three different routes: the P450 cytochrome system 
(CYP450), P glycoprotein (PgP), and the members of the 
organic anion transport polypeptide (OATP) family.100 Other 
possibilities include displacement of a protein bound drug 
fraction. The most relevant and hence the most thoroughly 
studied of these have been those involving CYP450.
Given the previous background, studies to assess potential 
pharmacological drug interactions for new antihistamines 
comprise at least 2 general axes: interactions that could 
impair cardiac safety, mainly as a consequence of a pharma-
cokinetic interaction at the metabolic level, and interactions 
that could impair CNS safety, mainly as a consequence 
of a pharmacodynamic interaction with recognized CNS 
depressants.
The metabolism of ebastine to carebastine was dem-
onstrated in rat small intestine and liver tissue.101 Ebastine 
undergoes extensive metabolism to form desalkylebastine 
and hydroxyebastine.102–104 Hydroxyebastine is subsequently 
metabolized to carebastine. Until recently, the specific hepatic 
CYP450 enzymes involved in these processes had eluded us. 
However, utilizing chemical inhibition and kinetic analysis 
studies in human liver microsomes, Liu et al104 concluded 
that dealkylation of ebastine and its metabolites is mainly 
catalyzed by CYP3A4, and CYP3A5 to a lesser degree. More-
over, hydroxylation reactions are preferentially catalyzed by 
CYP2J2. Thus, when a therapeutic dose of ebastine is given 
together with therapeutic doses of other drugs metabolized 
by CYP3A4, a pharmacokinetic interaction can occur, usu-
ally producing increases in ebastine plasma concentrations. 
This interaction is associated with the possible prolongation 
of the QTc interval. Whether this prolongation occurs or 
not has been subject to debate, as discussed in the previous 
section. Nevertheless, even if it is present, it does not seem 
to be clinically relevant.
CYP3A4 inhibitors such as cimetidine, clarithromycin, 
clotrimazole, erythromycin, fluoxetine, gestodene and keto-
conazole could increase the risk of toxic concentrations of 
substances such as ebastine that are metabolized via the 
CYP3A4 pathway.100 To date ebastine has been investigated 
in drug interaction studies with ketoconazole, erythromycin 
and cimetidine. The first two of these studies were reviewed 
in a previous section of this manuscript.
Van Rooij et al105 studied the influence of cimetidine 
in the metabolism of ebastine. They conducted a double-
blind, placebo-controlled, randomized, crossover study in 
which 12 volunteers were administered a single dose of 
ebastine 20 mg on day 2 of a multiple administration of 
cimetidine (400 mg tid and 800 mg in the evening on the 
day preceding ebastine administration and 400 mg 4 times Journal of Asthma and Allergy 2009:2 84
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daily on the following 2 days) or placebo. Blood samples 
for determination of ebastine and carebastine were taken 
over the course of the last 2 days. Ebastine concentra-
tions were only detected in 1 subject and were negligible. 
The authors detected no significant effect of cimetidine on 
the conversion of ebastine to carebastine or on carebastine 
kinetics (AUC0–∞ = 4049 ± 985 ng*h/mL after cimetidine 
vs 3795 ± 959 ng*h/mL after placebo; 95% CI of the 
difference: −412 to 919). Furthermore, they did not find a 
significant effect on blood pressure or heart rate and sedation 
was not observed.
Based on the analysis of a series of patients receiving 
therapeutic anticoagulation, Garcia-Vallejo et al106 sug-
gested that ebastine, loratadine and cetirizine showed 
similar pharmacokinetic interactions when combined with 
acenocoumarol, perhaps due to hepatic enzymatic induction. 
Nevertheless, they also stated that this interaction did not 
result in a high rate of alterations in the international nor-
malized ratio (INR) values or hemorrhagic events, and they 
concluded that ebastine can be safely administered in patients 
receiving oral anticoagulation. Besides acenocoumarol, drug 
interaction studies of ebastine 20 mg with theophylline or 
warfarin have also been performed and no interactions have 
been reported.55
Mattila et al did not detect any pharmacokinetic interac-
tions between ebastine and ethanol or diazepam in healthy 
subjects.107,108 They performed 2 double-blind, crossover 
studies in which ebastine 20 mg and placebo were each 
administered for 1 week . On day 6, drug effects were 
assessed and on day 7 of both periods, ethyl alcohol 0.8 g/kg 
or diazepam 15 mg were given. No pharmacokinetic inter-
actions were observed, meaning that no change in ebastine, 
ethanol, or diazepam plasma levels was observed. Pharma-
codynamic results (CNS effects) will be discussed in the 
following section (lack of CNS effects).
It is of note that some drugs (eg, azithromycin, cimetidine, 
digoxin, erythromycin, fluoxetine, or ketoconazole) that act as 
substrates or modulators of PgP activity also act similarly in 
relation to CYP3A4 and OATP.100 Certain H1 antihistamines 
are PgP substrates (eg, fexofenadine, loratadine) and, as 
such, their bioavailability and clearance can be compromised, 
resulting in higher concentrations of antihistamine. However, 
drugs that are able to induce PgP yield a lesser concentration 
of the antihistamine when co-administered and this interac-
tion would therefore result in a decrease in antihistamine 
efficacy. For ebastine, its metabolite carebastine has been 
shown to be a substrate of PgP-mediated efflux from the brain 
at the blood–brain barrier, and a second efflux system is also 
possibly involved. The relatively low affinity of the uptake 
transport system for carebastine limits the brain distribution 
of ebastine/carebastine.109
Lastly, both ebastine and carebastine are highly protein-
bound (98%) in the circulation, but the volume of distribution 
has been reported to be between 90 and 140 L.35 Given this 
combination of factors, protein plasma binding displacement 
drug interactions are of little concern.
Drug interactions after co-administration of ebastine 
with a number of other drugs (CYP3A4 inhibitors or drugs 
with sedative effects) have been correctly investigated. 
According to the results of clinical trials performed to 
date, there seems to be no danger of clinically relevant 
drug interactions in terms of either cardiac or CNS safety. 
Nevertheless, to be classified as a third-generation com-
pound, it is desirable that a new antihistamine has no drug 
interactions at all.
Lack of CNS effects
One of the major disadvantages of first-generation antihis-
tamines is the sedation they cause. This not only limits their 
use but can also cause accidents while driving and working, 
and contribute to a decline in productivity and learning 
efficiency.110–113 However this unwanted CNS effect seems 
to develop tolerance, that is, to dissipate after 4 to 7 days of 
regular therapy. Sedation induced by these first-generation 
antihistamines is provoked by their penetration through the 
blood–brain barrier and consequent occupation of brain 
H1 receptors.114 Thus, the main challenge facing second-
generation antihistamines has been to block passage through 
the blood–brain barrier.115
Preclinical and clinical data indicate that ebastine has no 
sedative effect.116 The potency and potential CNS effects of 
ebastine have been studied by means of competition binding 
and functional assays. In vitro, both ebastine and carebastine 
have shown a high affinity for the H1 receptor in the guinea 
pig cerebellum. Furthermore, they inhibit [3H]-mepyramine 
binding with a Ki of 7.1 nM and 7.9 nM, respectively. 
This effect is twice as potent as that shown by terfenadine 
(Ki = 14.3 nM), but less potent than that seen with astem-
izole (Ki = 1.7 nM). In experiments measuring inhibition of 
[3H]-mepyramine binding to rat cerebral cortex histamine H1 
receptors in vitro, the concentration of drug required to inhibit 
binding by 50% (IC50) was 0.32 µmol/L for ebastine and 
0.17 µmol/L for carebastine. These values, similar to those 
for other second-generation antihistamines, indicate 20 to 
40 times less affinity for cerebral H1 receptors than the first-
generation drug chlorpheniramine (IC50 0.01 µmol/L).36Journal of Asthma and Allergy 2009:2 85
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In vivo, the oral dose required to cause 50% inhibition of 
[3H]-mepyramine binding to cerebral H1 receptors (ID50 value) 
was 10.3 mg/kg, indicating that ebastine is more than 
500 times less active than chlorpheniramine (0.02 mg/kg). 
This emphasizes the fact that it does not easily cross the 
blood–brain barrier and supports its categorization as a non-
sedating antihistamine.36
By comparing in vivo cerebral binding data and in vivo 
peripheral pharmacological data, it is possible to quantify the 
sedation potential of a given antihistamine. Different stud-
ies have shown that the ID50 value for in vivo inhibition of 
[3H]-mepyramine binding in mouse cortex is 25.6 mg/kg and 
the ED50 value for histamine-induced dermal lesions in mice 
H1 receptors is 0.09 mg/kg. These values indicate the calcu-
lated sedation potential is 0.0035, as opposed to 0.066 and 
555 for terfenadine and d-chlorpheniramine respectively.36
CNS penetration has been extensively studied. As ebastine 
is rapidly metabolized to carebastine, we will focus on this 
metabolite. First, carebastine’s polarity makes it more difficult 
to penetrate the CNS than ebastine.117 Secondly, carebastine 
does not occupy brain H1 receptors in parallel with increasing 
plasma carebastine concentration, possibly because carebas-
tine is a substrate of P-glycoprotein and other transporters 
expressed on the blood-brain barrier, which serve as efflux 
pumps from the brain to the blood.109 Using the BUI (brain 
uptake index) method in rats, the efflux of [14C] carebastine 
by the transporters was not inhibited by a large amount of 
nonlabelled carebastine (150 µM) which was about 650 
times the plasma concentration obtained from a phase I 
clinical trial.118 This means that although it is theoretically 
a saturable system, in practice it is not saturated. Ebastine 
would therefore cause little sedation even when associated 
with a high plasma carebastine concentration as a result of 
overdosing or metabolic inhibition.119
In clinical trials the most common adverse effects 
experienced by patients after administration of ebastine have 
been headache and somnolence, though these effects have 
not been able to be differentiated from placebo.34 Besides 
this field evidence, information from experimental studies in 
healthy volunteers specifically performed to assess possible 
CNS effects is available.
At least 4 studies have been performed to assess the CNS 
effects of ebastine in laboratory conditions. Psychomotor 
tests, VAS, and pharmaco-EEG have been used to test the 
drug against placebo and/or positive comparators (ie, vera). 
Additionally, a car driving performance study has been car-
ried out in real traffic conditions, comparing ebastine with 
placebo and a positive comparator. Interactions with ethanol 
and diazepam and the resulting effect on psychomotor 
performance have also been evaluated. Finally, central 
H1 receptor occupancy has been quantified by means of 
PET scans. Even if all these studies have been performed in 
healthy volunteers, their value as useful biomarkers of what 
happens in the clinical scenario is well known.
In a single blind, cross-over, placebo controlled study 
(n = 9), Vincent et al116 assessed the effects of 10 mg and 
50 mg of ebastine on cardiovascular, autonomic and psycho-
motor function in healthy subjects. Evaluation was performed 
by means of psychomotor tests, both subjective (such as VAS 
for sedation and categorical questioning on mood) and objec-
tive (critical flicker fusion threshold, choice reaction time and 
recognition time). Autonomic tests measuring blood pressure, 
heart rate, salivary secretion and the standing to lying ratio 
have also been conducted. Besides no effect on blood pressure 
or heart rate, or any evidence of anticholinergic activity, 
ebastine did not impair psychomotor performance as assessed 
by the critical flicker fusion threshold. However, there was a 
marginal effect on the overall choice reaction time; this was 
most apparent at the higher dose and its clinical significance 
remains doubtful. Moreover, ebastine 10 mg had no effect on 
sedation, although ebastine 50 mg caused a modest increase 
in indices of sedation (P  0.05).
CNS effects in healthy male volunteers were also explored 
by Hopes et al120 in a double blind, placebo-controlled trial 
with a latin square design (n = 16). Single doses of ebastine 
10 and 20 mg were compared to placebo and to clemastine, 
a H1 receptor antihistamine that is reported to affect visual-
motor coordination and reaction time, and to cause subjective 
tiredness. The most relevant aspects of behaviour were evalu-
ated: vigilance as measured by quantitative pharmaco-EEG, 
cognitive performance, visual motor coordination and subjec-
tive estimates of sedation. While clemastine produced impair-
ment of psychomotor performance, drowsiness, a selective 
effect on cognitive processes and a general decrease in 
vigilance, ebastine did not differ at any time from placebo. 
Moreover, ebastine also differed positively from clemastine 
in the EEG features of vigilance (eg, a smaller increase in 
relative deltaF power [P  0.05] and a smaller decrease in the 
relative power of the alpha1 frequency band) and concerning 
its effect on pursuit tracking and subjective rating of drowsi-
ness and general discomfort.
Hindmarch et al121 performed a double-blind, randomized, 
5-period, cross-over study to evaluate the cognitive and 
psychomotor effects of ebastine (10, 20, and 30 mg) com-
pared with sustained-release triprolidine (10 mg) and placebo 
in healthy volunteers (n = 10). Following each dose, the Journal of Asthma and Allergy 2009:2 86
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subjects had to perform a battery of tests that comprised the 
critical flicker fusion threshold, choice reaction time, the 
simulated car tracking task, Sternberg memory scanning 
task, assessment of subjective sedation, and subjective 
evaluation of sleep by means of the Leeds Sleep Evaluation 
Questionnaire. Triprolidine produced an overall increase of 
the peripheral reaction time component of the simulated car 
tracking task, a clear decrement on the Sternberg memory 
scanning task in comparison to placebo (P  0.05), and 
significantly greater subjective reports of sedation when 
compared with placebo (P  0.05). Ebastine was found to 
be free of impairment on objective aspects of psychomotor 
and cognitive function.
Tagawa et al122 performed another single-blind, random-
ized, cross-over study to evaluate the effect of ebastine 10 mg 
on cognitive performance compared to (+) chlorpheniramine 
2 mg and 6 mg and placebo. Several attention demanding 
cognitive tasks (visual discrimination time task [VDT], 
choice reaction time task [CRT] and simple reaction time 
task [SRT]) were performed by healthy volunteers (n = 24) 
at the moment when the plasma drug concentration was 
expected to be at its maximum value. Ebastine was found not 
to affect task performance or subjective sleepiness, while (+) 
chlorpheniramine 2 and 6 mg caused concentration-related 
impairment of task performance (eg, ratios of after/before 
dosing: placebo [0.998 ± 0.113] vs (+) chlorpheniramine 
2 mg [1.103 ± 0.083; P  0.05] or (+) chlorpheniramine 6 mg 
[1.170 ± 0.139; P  0.001] in a 7 msec visual discrimination 
time task. Feelings of sleepiness in the chlorpheniramine 
groups also increased compared with the placebo group 
(placebo vs (+) chlorpheniramine 2 and 6 mg: P  0.05).
Brookhuis et al123 performed a double-blind, placebo-
controlled trial with triprolidine 10 mg as an active control. 
They tested ebastine 10, 20, and 30 mg on several parameters 
of driving performance in real traffic in healthy volunteers. 
Driving performance was tested on day 1 and after a 5-day 
treatment. As expected, triprolidine 10 mg significantly 
increased the amount of weaving and the delay in following 
speed maneuvres of a leading car, compared to placebo, 
whereas ebastine did not produce any significant change at 
any dose.
Clinically significant drug interactions can occur 
when 2 or more drugs are taken in combination.124 With 
antihistamines being among the most widely prescribed 
medications in the world, and as result of their widespread 
over-the-counter availability, a large number of ambulant 
patients using antihistamines could also concomitantly 
take other drugs. Consequently, understanding drug–drug 
interaction issues associated with antihistamines is a pertinent 
topic.125 A relevant pharmacodynamic drug interaction is one 
that consists of additive CNS depression effects. In terms of 
CNS safety, newer-generation agents have improved profiles 
over first-generation agents.126,127 However, even the minimal 
potential of a drug to produce sedation could be important, 
since this sedative effect can be further worsened by other 
CNS depressant drugs, such as antidepressants, sedatives, 
narcotic pain relievers, and alcohol.128
In the clinical study for the evaluation of interactions 
between ebastine and ethanol, Mattila et al108 evaluated 
the performance of volunteers by means of objective tests, 
such as digit symbol substitution, flicker fusion threshold, 
Maddox wing, nystagmus, simulated driving, and body 
balance. Subjective tests included VAS and questionnaires. 
Ebastine did not impair performance either objectively or 
subjectively. Ethanol impaired performance in most objec-
tive tests and produced clumsiness, muzziness, and mental 
slowness, while these effects were not increased or modified 
in any way by ebastine.
Using a very similar design to their ethanol-ebastine 
interaction study, Mattila et al107 performed a double-blind, 
crossover study in which ebastine 20 mg or placebo were 
administered for 1 week each. On day 7 of both periods, 
volunteers were given diazepam 15 mg and the interaction 
between diazepam and ebastine was assessed. Performance 
was assessed by objective tests (digit symbol substitution, 
flicker fusion threshold, Maddox wing, simulated driving, and 
body balance). Subjective tests included VAS and question-
naires. Diazepam produced impaired performance in objec-
tive tests, and volunteers experienced drowsiness, weakness, 
clumsiness, mental slowness and poor performance according 
to the VAS. Ebastine, again, did not modify or increase the 
effects elicited by diazepam.
Interestingly, there is a study where the measurement 
of central H1 receptor occupancy in humans after ebastine 
intake has been assessed. In a single-blind, randomized, 
crossover study performed by Tagawa et al119 H1 receptor 
occupation by oral ebastine 10 mg, (+) chlorpheniramine 
2 mg and 6 mg and placebo was studied using PET, in healthy 
volunteers. Thereafter, PET scans with [11C]-doxepin, a potent 
H1 receptor antihistamine, were conducted near the tmax 
reported for both drugs (90 minutes scanning). The binding 
potential of doxepin (BP = Bmax/Kd) for available brain 
H1 receptors was imaged on a voxel-by-voxel basis through 
graphical analysis and H1 receptor occupancy was calculated 
in several H1 receptor rich regions (mainly cortex, anterior 
cingulate cortex [ACC] and thalamus) using statistical Journal of Asthma and Allergy 2009:2 87
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parametric mapping (SPM96). H1 receptor occupancies were 
approximately 9.9, 3.2 and 14.4% in the ebastine 10 mg group 
(cortex, ACC and thalamus, respectively), approximately 
50.3 (P  0.001, 95% CI for difference in the mean recep-
tor occupancies: 26.6–54.3 vs ebastine) 49.2 (P  0.001, 
95% CI: 24.3-67.5 vs ebastine) and 49.7% (P  0.01, 95% 
CI 14.8 to 55.9 vs ebastine) in (+) chlorpheniramine 2 mg. 
Comparisons against (+) chlorpheniramine 6 mg were in the 
same range and were also statistically different. Furthermore, 
receptor occupancies increased with increasing plasma 
concentrations of (+) chlorpheniramine (cortex: r = 0.9021 
[P  0.001]; ACC: r = 0.7483 [P = 0.0051]; thalamus: 
r = 0.5874 [P = 0.0446]), but not with concentrations of 
carebastine. Worth mentioning is the fact that other second 
generation antihistamines, such as epinastine, terfenadine, 
azelastine, mequitizine and astemizole, occupy 10% to 30% 
of brain H1 receptors.129
The lack of CNS effects is one of the characteristics that 
has been most thoroughly and satisfactorily assessed for 
ebastine. In vitro, in vivo, and clinical studies evaluating 
subjective and objective variables have made it clear that 
ebastine does not produce sedation at therapeutic doses. 
Drug interaction studies with classical CNS depressants 
have also discarded a synergistic effect. Furthermore, neu-
roimaging studies have now added to formerly available 
clinical evidence.
Pharmacological approach
Receptor antagonism or inverse agonism
The H1 receptors belong to the superfamily of G protein 
receptors (GPCRs) and are encoded on human chromo-
some 3. The cloning and expression of these elements 
by recombinant cells has allowed us to know that these 
receptors exhibit spontaneous activation of their intracellular 
messengers, requiring no binding by an agonist at surface 
level to be in an active state. This “constitutive activity” 
is attributable to an active and an inactive conformation 
coexisting in equilibrium.8 As a result, the drugs that act 
upon these receptors have been reclassified. Accordingly, 
if the ligand stabilizes the active conformation, then the 
drug is an agonist, whereas if the inactive conformation is 
stabilized, the drug is said to be an inverse agonist.71 In this 
sense, histamine is an agonist and H1 antihistamines are 
inverse agonists, rather than H1 receptor antagonists.39 Until 
now, all existing H1 antihistamines evaluated have proved 
to be inverse agonists.39 The advantages or disadvantages to 
develop a real H1 receptor antagonist instead of an inverse 
agonist are not yet clearly established.
H3 receptors
H3 receptors, first described in 1983, have been reported to 
play a role as autoreceptors in the regulation of histamine 
synthesis and release from tissue nerve.130 Localization stud-
ies in rodents have shown predominance in distinct regions 
of CNS, such as cerebral cortex, hippocampus, amygdala, 
nucleus accumbens, globus pallidus, striatum, and hypothala-
mus. Peripherally, these receptors have been identified in the 
gastrointestinal tract, airways, and cardiovascular system. 
The fact that H3 receptors are expressed in postganglionic 
cholinergic nerves in human bronchi has suggested that 
their stimulation may act as a protective mechanism against 
excessive bronchoconstriction.
Several centrally acting imidazole and nonimidazole 
based antagonists and inverse agonists have been studied 
in recent years for myriad conditions (eg, cognitive impair-
ment, narcolepsy, obesity, diabetes mellitus, and neuropathic 
pain).131 Peripherally acting hybrid structures are created by 
combining histamine H1 with H3 pharmacophores to treat 
nasal congestion in allergic rhinitis,131 as it has been suggested 
that cutaneous itch and nasal congestion may be mediated 
both the H1 and H3 receptors.132–134
Combinations with H1 antihistamines have been reported 
in the field of imidazole and non-imidazole containing 
ligands.131 A ketopiperazine compound, GW-784568X 
(GlaxoSmithKline) , is now patented and has already passed 
a clinical phase I/II study aiming to assess the safety and 
efficacy of intranasal application in patients with allergic 
rhinitis.131 Currently, GlaxoSmithKline’s pipeline lists 
2 histamine H1/H3 dual antagonists (GSK1004723 and 
GSK835726) in phase II of clinical development, targeted 
on allergic rhinitis.135 GSK1004723 has already been 
administered intranasally in a phase I clinical trial, while 
GSK835726 is planned for a similar study.131 The success 
of this approach will be known shortly.
H4 receptors
A fourth histamine receptor (H4) with very high affinity for 
histamine has recently been described.136,137 Its presence on 
eosinophils had been suggested previously.138–140 but it had 
not been identified as such.37 Compared with the H1 and H2 
receptors, the H4 receptor is chiefly found in dendritic cells, 
mast cells, eosinophils, monocytes, basophils, and T cells, sug-
gesting perhaps an interesting target for drug development.
The antihistamines that are currently used in the clinic 
have little, if any, affinity for the H4 receptor. However, it has 
been observed that this receptor is involved in inflammatory 
and immunomodulatory responses in vitro and in vivo.37 Journal of Asthma and Allergy 2009:2 88
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It has been demonstrated, for instance, that histamine acting 
through H4 receptors can induce chemotaxis of murine mast 
cells in vitro.141 Moreover, in vivo redistribution of mast cells 
to the tracheal epithelium has been successfully blocked by 
systemic administration of the H4 receptor antihistamine JNJ 
7777120.142 It has been hypothesized that this latter effect is 
probably linked to the epithelial lining of the nasal mucosa in 
rhinitic responses to allergens.143,144 Additionally, activation of 
H4 receptors can induce chemotaxis of human eosinophils and 
dendritic cells,145,146 and in human mast-cell precursors this 
activation can synergize with other chemoatractants,138,147,148 
such as CXCL12, a constitutive chemokine (ligand of 
CXCR4 and CXCR7) that is expressed in the skin and air-
way epithelium and plays a significant role in allergic airway 
diseases.149,150
All the above described properties, and the emerging role 
of the H4 receptor in inflammation, have spurred new inter-
est in the functions of histamine in inflammation, allergy, 
and autoimmune diseases.37 The apparent overlap in the 
functions of H1 and H4 receptors suggests that H4 receptor 
antihistamines could perhaps work in synergy with H1 receptor 
antihistamines for the relief of conditions such as asthma, a 
therapeutic area that has eluded H1 antihistamines to date.37
Conclusions
Current evidence shows that like other second-generation 
H1 antihistamines, ebastine can modulate the allergic 
inflammatory process, and that this property might be directly 
linked to the amelioration of nasal congestion. To corroborate 
this putative effect, a clinical trial with one or more positive 
comparators and placebo is needed.
For potency, efficacy, and effectiveness, ebastine 
has shown interesting properties in relation to other 
antihistamines, although their therapeutic relevance has not 
been satisfactorily demonstrated. In other words, ebastine 
does not differ as much as would be needed to be considered 
a third-generation agent.
Despite initial concerns by the FDA, clinical trials 
and clinical evidence from the clinical development and 
postmarketing stages have provided sufficient evidence to 
eliminate any major cardiac toxicity problem when the drug 
is used at the recommended doses. In retrospect, a thorough 
QT/QTc study, as currently defined, might have provided 
valuable information on the cardiac safety of ebastine and 
possibly would have ruled out the need for further studies.
Drug interactions after co-administration of ebastine with 
a number of other drugs have been correctly explored, in 
particular, CYP3A4 inhibitors or drugs with sedative effects. 
Results have demonstrated that there seems to be no danger 
of clinically relevant drug interactions.
A lack of CNS effects has been correctly and exhaustively 
studied. Ebastine does not produce sedation at therapeutic 
doses, and drug interaction studies with classical CNS depres-
sants have also eliminated a synergistic effect. Neuroimaging 
studies have added to the available clinical evidence.
Recently, other research lines have been investigated to 
obtain novel agents. For instance, the potential overlap of 
functions between H1 and H4 receptors has spurred new hope 
for the development of a new generation of antihistamines. 
In this regard, hybrid agents are being tested.
In conclusion, ebastine is a H1 antihistamine with an inter-
esting and widely proven therapeutic profile. It is one of the 
best documented second-generation antihistamines. However, 
taking CONGA recommendations into account, its classifica-
tion as a third-generation antihistamine is far from applicable. 
It is still going to be some time before a novel agent, meriting 
the denomination of a third-generation agent, is developed.
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